Stocklore

Pfizer Inc. (PFE)

Biotech & Health · US stock

What changed in recent filings

  • Institutions — 7 new13F · as of end of 2026 Q2
  • Free cash flow declined recentlyDec 31, 2025 → Jun 28, 2026

What changed in recent SEC filings — factual, not a buy/sell recommendation.

Institutions holding Pfizer Inc.

How many of the institutions we track reported holding this stock, quarter by quarter.

max 8
2019 Q1 · 12019 Q2 · 22019 Q3 · 22019 Q4 · 22020 Q1 · 52020 Q2 · 32020 Q3 · 42020 Q4 · 22021 Q1 · 32021 Q2 · 32021 Q3 · 72021 Q4 · 62022 Q1 · 62022 Q2 · 42022 Q3 · 52022 Q4 · 52023 Q1 · 52023 Q2 · 42023 Q3 · 42023 Q4 · 42024 Q1 · 32024 Q2 · 42024 Q3 · 32024 Q4 · 42025 Q1 · 62025 Q2 · 42025 Q3 · 22025 Q4 · 32026 Q1 · 22026 Q2 · 8
19 Q122 Q326 Q2

2019 Q1: 1 → 2026 Q2: 8 institutions

Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.

Which institutions hold Pfizer Inc.

Institutions we track that reported holding this stock in their most recent 13F.

  • Dodge & Coxunder 0.01% of portfolio · held as of 2019 Q1 or earlier
  • Tudor Investment CorpNew this quarter0.02% of portfolio · since 2026 Q2
  • Bridgewater AssociatesNew this quarter0.02% of portfolio · since 2026 Q2
  • Pzena Investment Management0.42% of portfolio · held as of 2026 Q2 or earlier
  • National Pension Service (Korea)0.23% of portfolio · held as of 2026 Q2 or earlier
  • Caisse de depot (Quebec)0.01% of portfolio · held as of 2026 Q2 or earlier
  • GQG Partners0.01% of portfolio · held as of 2026 Q2 or earlier
  • Capital World Investors0.06% of portfolio · held as of 2026 Q2 or earlier

Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.

Company overview

A large global pharma company whose challenge is securing new growth drivers after COVID-19 vaccine and treatment revenue. It bolstered its oncology portfolio with the Seagen acquisition.

What is the Biotech & Health sector?

Pharma, biotech, and medical devices. Driven by trial-result events.

Pfizer Inc. is classified under the Biotech & Health sector. See peers below.

Pfizer Inc. key financials

Based on SEC filings · as of Jun 28, 2026

9.0%
0.71x
as of Jun 28, 2026

Tap a metric name to see its meaning in the glossary.

Pfizer Inc. vs Biotech & Health sector benchmark

Median of 35 representative sector stocks · SEC filings · factual comparison (not advice)

Revenue growth (YoY)
-0.2%vs benchmark 8.4%↓ below
Net margin
6.8%vs benchmark 15.0%↓ below
ROE
9.0%vs benchmark 14.3%↓ below

A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.

PFE segment revenue mix trend

Quarterly change in segment revenue share · verified from SEC filings

Jun '24Dec '24Jun '25Mar '26
United States 60%International Developed Markets 24%International Emerging Markets 16%

4 quarters with a different segment breakdown were omitted (filing basis changed).

ETFs holding Pfizer Inc.

Per SEC N-PORT · 2026-06-30 · by weight · factual

XLVState Street(R) Health Care Select Sector SPDR(R) ETF
2.39%
DVYiShares Select Dividend ETF
2.22%
VYMVANGUARD HIGH DIVIDEND YIELD INDEX FUND
0.63%
VTVVANGUARD VALUE INDEX FUND
0.51%
SPY
0.21%
VOOVANGUARD 500 INDEX FUND
0.21%
IVViShares Core S&P 500 ETF
0.21%
VTIVANGUARD TOTAL STOCK MARKET INDEX FUND
0.19%
ITOTiShares Core S&P Total U.S. Stock Market ETF
0.19%
RSPInvesco S&P 500 Equal Weight ETF
0.19%

PFE on Stocklore

  • Revenue by segmentsegment weights verified from SEC filings, YoY changes, growth drivers and concentration
  • Financials & earnings quality6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
  • 13F institutional holdingsholdings and weight changes of major institutions (45-day delay)
  • Sector-relative metricsValuation and growth compared with the Biotech & Health average
See full PFE analysis →

Peers · Biotech & Health

PFE FAQ

What is Pfizer Inc. (PFE)?

A large global pharma company whose challenge is securing new growth drivers after COVID-19 vaccine and treatment revenue. It bolstered its oncology portfolio with the Seagen acquisition.

What sector is Pfizer Inc. in?

Pfizer Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.

What are Pfizer Inc.'s key financials?

As of Jun 28, 2026 in SEC filings: Revenue growth (YoY) -0.2%, Net margin 6.8%, ROE 9.0%, Debt-to-equity 0.71x. Definitions and interpretation are available on Stocklore.

Where can I analyze Pfizer Inc. (PFE) stock?

On Stocklore you can see PFE's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.

Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.

Not an investment adviser and not personalized investment advice; not a discretionary management service. No trade recommendations, no target prices, no execution or brokerage. We do not recommend or guarantee any purchase, sale, or returns. Investment decisions and their outcomes are your own.

Stocklore · CEO Lee Seung-jae · Business reg. no. 764-36-01607 · E-commerce permit 2026-Jeonju Wansan-0476 · Tel +82-70-7954-4939 · S120, Rm 302, 3F, 21 Jungsanjungang-ro, Wansan-gu, Jeonju, Jeonbuk, Korea